Applied DNA Sciences (APDN, $8.89) gets FDA nod on emergency clinical use of its covid-19 test
Applied DNA Sciences got an authorization from the U.S. Food and Drug Administration (FDA) for emergency clinical use of its covid-19 test, Linea.
"This extraordinary achievement highlights the company’s commitment to combating the covid-19 pandemic both locally and nationwide," Chief Executive James Hayward said in a statement.
The machine that performs the test can process 94 samples per hour and more than 2,000 tests per day. The FDA has authorized emergency use for about 50 molecular tests that can detect COVID-19
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Advertisement
General Information
a provider of botanical deoxyribonucleic acid based security and authentication solutions
Industry InvestmentManagers
Advertisement